News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419 Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
GC4419 met primary endpoint, achieving 92 percent reduction in duration of severe oral mucositis (SOM) in patients with head and neck cancer GC4419 also demonstrated reduction in SOM incidence and severity, and was well tolerated Abstract to be featured in 2018 Best of ASCO program​​​​​​​ MALVERN,
View HTML
Toggle Summary Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual Meeting
GC4419 demonstrated clinically significant reduction in duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer Trial investigator Dr. Carryn Anderson honored with Steven M. Grunberg Memorial Award for excellence in cancer research MALVERN, Penn.
View HTML
Toggle Summary Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting
MALVERN, Penn. — October 23, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from its Phase 2b clinical trial evaluating avasopasem
View HTML
Toggle Summary Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis
Tumor outcomes results from two-year follow-up of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese to be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium MALVERN, Pa. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc.
View HTML
Toggle Summary Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin
Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented at ASCO 2020 Virtual Scientific Program MALVERN, Penn., May 29, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Galera Therapeutics Announces Dosing of First Patient in Phase 1/2 Pancreatic Cancer Clinical Trial of GC4419
First Clinical Trial Evaluating Anti-Tumor Effect of GC4419 in Combination with Radiation MALVERN, Penn. — Feb. 28, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy,
View HTML
Toggle Summary Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication
-- Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer -- -- Marks expansion of lead product candidate avasopasem manganese into second radiation toxicity indication -- MALVERN, Pa., Jan.
View HTML
Toggle Summary Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)
Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application MALVERN, Penn. — October 15, 2018 —  Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development
View HTML
Toggle Summary Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis
Enrolls First Patients in Late-Stage Trial of GC4419 in Head and Neck Cancer Patients MALVERN, PA – January 7, 2016  – Galera Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for GC4419, an investigational drug candidate, for
View HTML
Toggle Summary Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program
MALVERN, Pa., May 13, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a
View HTML